'The Contract Vaccine Manufacturing Market Will Reach $0.62 Billion in 2015' Predicts New Visiongain Report

visiongain

Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres

5 pages

English

Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres

A propos
Informations
Extrait

Description

'The Contract Vaccine Manufacturing'The Contract Vaccine Manufacturing Market Will Reach $0.62 Billion in 2015' Predicts New Visiongain Report PR Newswire LONDON, October 9, 2013 What's the outlook for producing vaccines? Visiongain's updated report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for those technologies. Our study lets you assess sales data at overall world market, submarket and national level. There you find the most promising and lucrative areas in the production of vaccines, helping your research and analyses. There's rising demand for those products and services. In particular, outsourced vaccine manufacturing will expand from 2013 to 2023, with growing revenues. Forecasts and other analyses to help you stay ahead in knowledge In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends. You receive 70 tables, 46 charts and two research interviews. You discover industry dynamics and growth potentials - the following sections show what you find in our new report. Discover prospects for the world market and submarkets Along with revenue prediction for the overall world market, you see forecasts to 2023 for these five submarkets: • Paediatric vaccines • Influenza vaccines • Adult prophylactic vaccines • Therapeutic vaccines • Contract vaccine manufacturing.

Informations

Publié par	visiongain
Publié le	09 octobre 2013
Nombre de lectures	10
Langue	English

Extrait

'The Contract Vaccine Manufacturing Market Will Reach $0.62 Billion in 2015' Predicts New Visiongain Report

PR Newswire

LONDON, October 9, 2013

What's the outlook for producing vaccines? Visiongain's updated report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for those technologies.

Our study lets you assess sales data at overall world market, submarket and national level. There you find the most promising and lucrative areas in the production of vaccines, helping your research and analyses.

There's rising demand for those products and services. In particular, outsourced vaccine manufacturing will expand from 2013 to 2023, with growing revenues.

Forecasts and other analyses to help you stay ahead in knowledge

In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends. You receive 70 tables, 46 charts and two research interviews.

You discover industry dynamics and growth potentials - the following sections show what you find in our new report.

Discover prospects for the world market and submarkets

Along with revenue prediction for the overall world market, you see forecasts to 2023 for these five submarkets:
• Paediatric vaccines
• Influenza vaccines
• Adult prophylactic vaccines
• Therapeutic vaccines
• Contract vaccine manufacturing.

You gain advantages by understanding trends, opportunities and challenges. Our investigation shows what will stimulate and restrain business.

Our work also breaks the main world forecast into leading geographical markets.

What prospects for leading regions and countries?

Developments worldwide will influence the market from 2013, especially production of vaccines in emerging countries. There exist many opportunities for pharma companies and contract manufacturing organisations (CMOs). See prospects for the industry.

You get individual forecasts to 2023 for eleven national markets, finding overall revenues:
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC nations).

Discover progress and outlooks. You assess the industry's future - hear about developments and find their significance. Our work explains, exploring many issues.

What affects vaccine manufacturing from 2013?

Our report discusses issues and events affecting that industry and market from 2013 onwards:
• Cell-based techniques - mammalian cell lines, avian-derived cells, plant-based processes and other methods
• Next-generation expression systems and vectors - increasing yields
• Recombinant DNA technologies
• Equipment, including single-use (disposable) bioreactors and prefilled syringes
• Product stability, lyophilisation and quality assurance programmes.

Also, we discuss these aspects of the field:
• Reasons, strategies and benefits for outsourcing production
• Services offered by CMOs
• Pandemic preparedness, bioterrorism, storage and distribution networks
• Pricing, regulation and governmental policy.

See what the future holds. You investigate technological, economic and political matters, finding emphasis on companies, competition and business outlooks.

Leading companies and 2015 market values

We predict that the world market for vaccines will reach $48bn in 2015, and expand further to 2023. Also, vaccine contract manufacturing will reach $0.62bn in 2015. That outsourcing segment holds great potential for investment, development and growth from 2013.

Preventive healthcare has rising importance. We review these leading producers:
• GlaxoSmithKline (GSK)
• Sanofi Pasteur
• Pfizer
• Merck
• Novartis.

Also, we profile these contract service providers:
• Baxter BioPharma Solutions
• Boehringer Ingelheim
• Catalent
• Charles River Laboratories
• IDT Biologika GmbH
• Lonza
• Meridian Life Science
• SAFC (Sigma-Aldrich Fine Chemicals)
• SynCo Bio Partners.

From 2013 to 2023, many opportunities will arise. Our work shows you the technological and commercial possibilities.

Eight ways Vaccine Manufacturing Technology and Services: World Market 2013-2023 helps

In particular, then, our investigation gives you the following knowledge:
• Revenues to 2023 for the overall world market and 5 submarkets - you discover the industry's future prospects
• Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - you see national sales predictions
• Profiles of 14 leading companies - you hear about activities, recent results, strategies and outlooks
• Predictions for outsourcing vaccine production - you assess developments and prospects for service providers (CMOs) and their clients
• Opinions on the sector - you read our interviews with authorities in the field
• Competition and opportunities influencing sales - you see what affects the future
• Discussions of what stimulates and restrains the industry and market - you explore business trends, drivers and restraints
• Prospects for established firms and those seeking to enter the sector - you assess needs, practices and outlooks for success.

You gain information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where financial prospects are good.

With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for insight.

Ordering now lets you discover commercial prospects to 2023

Visiongain's investigation is for everyone needing forward-looking analysis of the vaccines industry and market. You find data, trends and predictions. Please order our report now.

For an executive summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com or click on

http://www.visiongain.com/Report/966/Vaccine-Manufacturing-Technology-and-Services-World-Market-2013-2023

Companies listed in this report include:

Companies Listed

AAI Pharma Services
Acambis
Accugenix
ACIP (Advisory Committee on Immunization Practices)
Advanced Bioscience Laboratories
Aeras Global
AfriVax
Alpha Biologics
Althea Technologies
Amgen
AmProtein
Angel Biotechnology Holdings
Antigenics
ANVISA (National Health Surveillance Agency) Brazil
Aptuit
Artelis
AstraZeneca
ATMI LifeSciences
AVEO Pharmaceuticals
Bacteriological Institute of the Anhaltian Administrative Areas
Bavarian Nordic
Baxter
Baxter BioPharma Solutions
Bayer
Bayer Schering Pharma AG
Ben Venue Laboratories
Berna Biotech
Bharat Biotech International
Biken Japan
Bill and Melinda Gates Foundation
Binnopharm
Bioline
Biological E
Bio-Manguinhos
Biomay
Biomedical Advanced Research and Development Authority (BARDA)
Biovian
BioXcellence
Blackstone Group
Boehringer Ingelheim
Butantan
Cardinal Health
Catalent
Catalent Pharma Solutions
CDC (Centers for Disease Control and Prevention) US
Cellexus
Charles River Laboratories
Chemo-Sero-Therapeutic Research Institute
China National Biotec Group (CNBG)
Chiron
CHMP (The Committee for Medicinal Products for Human Use) Europe
Cook Pharmica
Crucell
CSL Behring
CSL Biotherapies
Cytovance Biologics
Daiichi Sankyo
Defense Advanced Research Projects Agency (DARPA)
Denka Seiken Company
Department of Health and Human Services (HHS)
DSM Biologics
DynPort
Eclipse Therapeutics
Eden Biodesign
Eurogentec Biologics
European Medicines Agency (EMA)
European Vaccine Manufacturers (EVM)
FDA (Food and Drug Administration), US
Frazier Healthcare
Fujifilm Diosynth Biotechnologies
GAVI Alliance
GE Healthcare
GlaxoSmithKline (GSK)
Goodwin Biotechnology
Grand River Aseptic Manufacturing
Health and Human Services (HHS)
Health Canada
Hospira
HTD Biosystems
Hualan Biological Engineering
IDT Biologika
Immune Pharmaceuticals
Impfstoffwerk Dessau-Tornau (IDT)
Innogenetics Biologicals
Institute of Technology in Immuno-biologicals of the Oswaldo Cruz Foundation
Intercell
International AIDS Vaccine Initiative (IAVI)
IntroGene
Irvine Scientific
Johnson & Johnson (J&J)
Jubilant HollisterStier
Kalon Biotherapeutics
Kitasato Institute
Klocke
Korean FDA
Kuhner
Lonza
Medicago
MedImmune
Merck & Co.
Merck Millipore
Merck Serono
Meridian Bioscience
Meridian Life Science
Millipore
Ministry of Health, Labour and Welfare (Japan)
MP Biomedicals
Nascent Biologics
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH), US
NICE (National Institute for Health and Clinical Excellence), UK
Novartis
Novavax
OHSU
Organon Teknika Corporation
Pall Life Sciences
Pantec
Paragon Bioservices
Pasteur Merieux Serums & Vaccines
Patheon
PBS Biotech
Pfenex
Pfizer
PharmAthene
Pierre-Guérin Biolafitte
ProBioGen
Protein Sciences Corporation
Refine Technology
Research Foundation for Microbial Diseases of Osaka University
SAFC (Sigma-Aldrich Fine Chemicals)
Sanofi (formerly sanofi-aventis)
Sanofi Pasteur MSD
Sartorius Stedim Biotech
Serum Institute of India
Shantha Biotech
Sigma-Aldrich
Sinovac
Synco Bio Partners
Teva Pharmaceutical Industries
Thermo Fisher
Thermo Scientific
UNICEF
United Nations
Vibalogics
Vivalis
Vivante GMP Solutions
Vrije Universiteit
Waisman Biomanufacturing
Wave Biotech (now part of GE Healthcare Life Sciences)
World Health Organization (WHO)
Wyeth
Xcellerex
Xencor
Zhejiang Tianyuan

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent business intelligence companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters and management reports focusing on the Energy, Telecoms, Pharmaceuticals, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.